{"id":"W4206959584","doi":"10.1016/s0140-6736(22)00010-1","title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","year":2022,"lang":"en","type":"article","venue":"The Lancet","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":686,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"National Institute for Health and Care Research; Roche","keywords":"Macular degeneration; Clinical trial; Phase (matter); Phases of clinical research; Degeneration (medical)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00167099,0.0002014146,0.001117028,0.00005644235,0.0002375523,0.00003340422,0.0001105976,0.0000466997,0.00009422791],"category_scores_gemma":[0.0002193944,0.0001323102,0.000267956,0.0001605817,0.00009271464,0.00004514381,0.0001203287,0.0001432085,0.000001380252],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008382783,"about_ca_system_score_gemma":0.00007145022,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003751385,"about_ca_topic_score_gemma":0.00001423396,"domain_scores_codex":[0.9982606,0.0003050416,0.0005595643,0.0003395352,0.000284273,0.0002510522],"domain_scores_gemma":[0.9988256,0.0003415845,0.000180211,0.0004605027,0.000070599,0.0001215742],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8320884,0.002439086,0.01111669,0.0007428074,0.004019755,0.0001865577,0.002553139,0.0009419107,0.04711054,0.00162618,0.002547639,0.09462732],"study_design_scores_gemma":[0.9119267,0.002912618,0.05767314,0.0001453571,0.005209178,0.0001620928,0.0002855381,0.002451506,0.008892233,0.00171534,0.008155892,0.0004704289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911484,0.001494288,0.0005446307,0.001803681,0.0001541118,0.004322605,0.0002819683,0.00003028823,0.0002200613],"genre_scores_gemma":[0.9983182,0.0002553489,0.0001878521,0.0002164595,0.000161296,0.000297474,0.0003717869,0.00002228567,0.0001692996],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09415689,"threshold_uncertainty_score":0.5395452,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04564152384848981,"score_gpt":0.3562724226406661,"score_spread":0.3106308987921763,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}